GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » Debt-to-Asset

Scandion Oncology A/S (OSTO:SCOL) Debt-to-Asset : 0.01 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology A/S Debt-to-Asset?

Scandion Oncology A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.41 Mil. Scandion Oncology A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Scandion Oncology A/S's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was kr40.43 Mil. Scandion Oncology A/S's debt to asset for the quarter that ended in Mar. 2024 was 0.01.


Scandion Oncology A/S Debt-to-Asset Historical Data

The historical data trend for Scandion Oncology A/S's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology A/S Debt-to-Asset Chart

Scandion Oncology A/S Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial - - 0.01 0.02 0.01

Scandion Oncology A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.01 0.01 0.01

Competitive Comparison of Scandion Oncology A/S's Debt-to-Asset

For the Biotechnology subindustry, Scandion Oncology A/S's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scandion Oncology A/S's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scandion Oncology A/S's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Scandion Oncology A/S's Debt-to-Asset falls into.



Scandion Oncology A/S Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Scandion Oncology A/S's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Scandion Oncology A/S's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scandion Oncology A/S  (OSTO:SCOL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Scandion Oncology A/S Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Scandion Oncology A/S's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Scandion Oncology A/S (OSTO:SCOL) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology A/S (OSTO:SCOL) Headlines

No Headlines